Patent intelligence · CA
CA 2670932
DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE
DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE
Patent details — CA 2670932
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Jun 26, 2008
- Expiration
- Jun 21, 2028
- Applicant
- BRACCO INT BV [NL]
- CPC classes
- A61P/4300
Quick answer
CA 2670932 (DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE) is held by BRACCO INT BV [NL]. Status: granted. Granted Jun 26, 2008. Expires Jun 21, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BRACCO INT BV [NL]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P/4300
More from BRACCO INT BV [NL]
Related pharmaceutical patents in our USPTO index.
-
IL 172160
Method for non-invasive quantification of perfusion in a tissue
granted -
EP 2117603
TARGETING UND THERAPEUTISCHE VERBINDUNGEN UND GASGEFÜLLTE MIKROVESIKEL MIT DIESEN VERBINDUNGEN
granted -
WO 2009076388
CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE
granted -
US 2008107607
TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
granted -
US 2008063603
ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM
granted -
CA 2631716
CONJUGUES VECTEUR DE CIBLAGE-PHOSPHOLIPIDES
granted -
US 2007128117
Ultrasound contrast agents and process for the preparation thereof
granted
Frequently asked questions
What is US patent 2670932?
CA 2670932 (DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE) is held by BRACCO INT BV [NL]. Status: granted. Granted Jun 26, 2008. Expires Jun 21, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2670932?
BRACCO INT BV [NL] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 2670932 expire?
Our index shows an expiration date of Jun 21, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.